Diamyd Medical has opened the first clinic for the recruitment of patients for a Phase III trial in Type 1 Diabetes
The first clinic has now been opened in the precision medicine Phase III trial DIAGNODE-3. The trial, designed to confirm the efficacy and safety of the antigen-specific immunotherapy Diamyd[®], will enroll approximately 330 patients aged 12 to 29 years recently diagnosed with type 1 diabetes and carrying the genetically defined HLA DR3-DQ2 haplotype.“DIAGNODE-3 is the result of years of hard work, important scientific advances and meticulous planning, and the fact that the first clinic has opened for patient recruitment is of course a significant milestone,” says Ulf Hannelius, CEO of